TAPUR is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancer and genomic alterations known to be drug targets. The results of a cohort of patients with colorectal cancer (CRC) withEligible patients had advanced CRC, no standard treatment options, measurable disease (RECIST), Eastern Cooperative Oncology Group performance status 0-2, adequate organ function, tumors withThirty patients were enrolled from August 2016 to August 2018; all had CRC with aThe combination of C + V has antitumor activity in heavily pretreated patients with CRC with